Multiple Sclerosis Research Repository

“Table 1. Reviewer Table. FDA-approved treatments for relapsing multiple sclerosis” (from: FDA CDER; application number: 211855Orig1s000; Diroximel fumarate (Vumerity); Clinical Reviews(s)”

-Review the images of this table and notice that under the “Efficacy Information” column only 2 DMTs have efficacy information about reduction in disability (Mitoxantrone and Ocrelizumab for PPMS) (*The claim here of Ocrevus showing a “24% reduction in disability progression (primary progressive MS)” is not accurate and has been discussed in previous posts*)

Published by

kaylin bower

Leave a comment